One of the reasons why the stock price fell is due to the results from a presentation of data from its Phase 1b/2 study in KRAS-mutated metastatic colorectal cancer (mCRC) as part of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) and the company also provided an additional data update from its mCRC clinical program and initial findings from its Expanded Access Program.
Is Crdf stock a good buy?
The financial health and growth prospects of CRDF, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F.
Is Cardiff oncology a good investment?
Cardiff Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Will Cardiff Oncology stock go up?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for Cardiff Oncology Inc have a median target of 17.00, with a high estimate of 25.00 and a low estimate of 9.00. The median estimate represents a +1,025.83% increase from the last price of 1.51.
Is Cardiff Oncology a buy right now?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last year. There are currently 4...
Are investors shorting Cardiff Oncology?
Cardiff Oncology saw a drop in short interest in February. As of February 15th, there was short interest totaling 2,220,000 shares, a drop of 28.4%...
When is Cardiff Oncology's next earnings date?
Cardiff Oncology is scheduled to release its next quarterly earnings announcement on Thursday, May 5th 2022. View our earnings forecast for Cardif...
How were Cardiff Oncology's earnings last quarter?
Cardiff Oncology, Inc. (NASDAQ:CRDF) posted its earnings results on Thursday, February, 24th. The company reported ($0.23) earnings per share for t...
What price target have analysts set for CRDF?
4 analysts have issued 1-year price objectives for Cardiff Oncology's shares. Their forecasts range from $14.00 to $25.00. On average, they anticip...
Who are Cardiff Oncology's key executives?
Cardiff Oncology's management team includes the following people: Mark Erlander , Chief Executive Officer & Director ( LinkedIn Profile ) Vicki...
Who are some of Cardiff Oncology's key competitors?
Some companies that are related to Cardiff Oncology include Tarsus Pharmaceuticals (TARS) , Jounce Therapeutics (JNCE) , Sutro Biopharma (STRO)...
What other stocks do shareholders of Cardiff Oncology own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeuti...
What is Cardiff Oncology's stock symbol?
Cardiff Oncology trades on the NASDAQ under the ticker symbol "CRDF."
Is Cardiff Oncology a buy right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last year. There are currently 3 buy ratings for the stock.
What stocks does MarketBeat like better than Cardiff Oncology?
Wall Street analysts have given Cardiff Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cardiff Oncology wasn't one of them.
When is Cardiff Oncology's next earnings date?
Cardiff Oncology is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.#N#View our earnings forecast for Cardiff Oncology.
How were Cardiff Oncology's earnings last quarter?
Cardiff Oncology, Inc. (NASDAQ:CRDF) announced its quarterly earnings results on Thursday, August, 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.02. The business earned $0.07 million during the quarter, compared to the consensus estimate of $0.07 million.
What price target have analysts set for CRDF?
3 Wall Street analysts have issued 12-month price objectives for Cardiff Oncology's shares. Their forecasts range from $25.00 to $26.00. On average, they anticipate Cardiff Oncology's share price to reach $25.33 in the next year.
Who are some of Cardiff Oncology's key competitors?
Some companies that are related to Cardiff Oncology include Tenaya Therapeutics (TNYA), Immunovant (IMVT), Adaptimmune Therapeutics (ADAP), iTeos Therapeutics (ITOS), Omega Therapeutics (OMGA), Immatics (IMTX), Sutro Biopharma (STRO), Mesoblast (MESO), Curis (CRIS), Aerie Pharmaceuticals (AERI), Taysha Gene Therapies (TSHA), Precision BioSciences (DTIL), TCR2 Therapeutics (TCRR), Acumen Pharmaceuticals (ABOS) and Osiris Therapeutics (OSIR).#N#View all of CRDF's competitors..
What other stocks do shareholders of Cardiff Oncology own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE), Livongo Health (LVGO), Co-Diagnostics (CODX), Novavax (NVAX), Fortress Biotech (FBIO), Maxar Technologies (MAXR), Ontrak (OTRK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA)..
Price Target and Analyst Ratings
On August 10, 2021 "HC Wainwright" gave "$25.00 - $26.00" rating for CRDF. The price target was set to $5.78+0.3%.
CRDF Stock Trend
The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected.
What is Cardiff Oncology?
(Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, in collaboration with scientists in the Center for Precision Cancer Medicine at the Massachusetts Institute of Technology (MIT), today announced that new gene signature and mechanistic analyses related to its ongoing Phase 2 trial of onvansertib in metastatic castrate-resistant prostate cancer (mCRPC) were featured in a virtual oral poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021.
Does Roku work with TV?
The Roku player connects to the user’s TV, and the company provides connected streaming services. On Roku’s end, profits come from a combination of audience monetization and advertiser engagement. Roku shares have slipped 25% since their recent peak in February this year.
Is Cardiff Oncology a biotechnology company?
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, today announced the appointments of Mani Mohindru, Ph.D., and Renee P. Tannenbaum, Pharm.D., as independent members of the Company's Board of Directors. Drs. Mohindru and Tannenbaum are filling the seats of outgoing directo